A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours

Dedeepiya,Vidyasagar   Devaprasad; Terunuma,Hiroshi; Deng,Xuewen; Baskar,Subramani; Manjunath,Sadananda  Rao; Senthilkumar,Rajappa; Murugan,Palanisamy; Thamaraikannan,Paramasivam; Srinivasan,Thangavelu; Preethy,Senthilkumar; Abraham,Samuel  J.K.

doi:10.3892/ol.2011.498

A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours

Authors:
- Vidyasagar Devaprasad Dedeepiya
- Hiroshi Terunuma
- Xuewen Deng
- Subramani Baskar
- Sadananda Rao Manjunath
- Rajappa Senthilkumar
- Palanisamy Murugan
- Paramasivam Thamaraikannan
- Thangavelu Srinivasan
- Senthilkumar Preethy
- Samuel J.K. Abraham
View Affiliations

Affiliations: Nichi-In Centre for Regenerative Medicine, Chennai, India, Biotherapy Institute of Japan, Tokyo, Japan
Published online on: November 29, 2011 https://doi.org/10.3892/ol.2011.498
Pages: 435-440

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The functional profile of natural killer (NK) cells has been reported to be lower in auto-immune haemolytic anaemia (AIHA). In this study, we report a comparative analysis of peripheral blood mononuclear cells (PBMNCs) and the in vitro expansion of NK cells in a patient with AIHA and cancer, with that of other cancer patients without AIHA. PBMNCs and in vitro NK-cell expansion of a 64-year old female patient with ovarian cancer and AIHA was compared with that of four other patients with cancer without AIHA who underwent autologous immune enhancement therapy (AIET). The NK cells were cultured using autologous plasma without feeder layers. The quantities of PBMNCs, NK cells and CD3-CD56+ cells were compared. The average quantity of PBMNCs per ml in Cases I to V were 10.71, 39.2, 49.26, 65.16 and 49.33x104, respectively, and the average maximum count of NK cells was 3.9, 1730.03, 1824.16, 1058.61 and 761x106, respectively. The average percentage of CD3-CD56+ cells in Cases I to V following in vitro expansion was 1.2, 65.7, 28.63, 65.9 and 40%, respectively. In the present study, probably the first in the literature, the in vitro expansion of NK cells was found to be significantly lower in the AIHA patient. Previously, only a lower NK-cell functional profile was reported. Further studies are required to establish the association between AIHA and NK-cell profile and in vitro expansion, and to find common antibodies between red blood cells (RBCs) and NK cells.

View Figures

View References

1	Goto S, Shirotani N, Hatakeyama M, et al: Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion). Anticancer Res. 22:2461–2464. 2002.PubMed/NCBI
2	Kimura H and Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 80:42–49. 1997. View Article : Google Scholar
3	Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI
4	Kono K, Takahashi A, Ichihara F, et al: Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 8:1767–1771. 2002.PubMed/NCBI
5	Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence an 11-year follow-up study of a general population. Lancet. 356:1795–1799. 2000.PubMed/NCBI
6	Montelli TC, Peraçoli MT, Gabarra RC, Soares AM and Kurokawa CS: Familial cancer: depressed NK-cell cytotoxicity in healthy and cancer affected members. Arq Neuropsiquiatr. 59:6–10. 2001. View Article : Google Scholar : PubMed/NCBI
7	Grunebaum E, Malatzky-Goshen E and Shoenfeld Y: Natural killer cells and autoimmunity. Immunol Res. 8:292–304. 1989. View Article : Google Scholar
8	Baxter AG and Smyth MJ: The role of NK cells in auto-immune disease. Autoimmunity. 35:1–14. 2002. View Article : Google Scholar
9	Cameron AL, Kirby B and Griffiths CE: Circulating natural killer cells in psoriasis. Br J Dermatol. 149:160–164. 2003. View Article : Google Scholar : PubMed/NCBI
10	French AR and Yokoyama WM: Natural killer cells and autoimmunity. Arthritis Res Ther. 6:8–14. 2004. View Article : Google Scholar
11	Conte R, Dinota A, Tazzari PL, Belletti D and Sermasi G: Analysis of natural killer cells in patients with idiopathic auto-immune hemolytic anemia. Vox Sang. 56:270–273. 1989. View Article : Google Scholar : PubMed/NCBI
12	Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N and Toi M: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI
13	Spanholtz J, Preijers F, Tordoir M, et al: Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 6:E207402011. View Article : Google Scholar
14	Hoffman PC: Immune hemolytic anemia - selected topics. Hematol Am Soc Hematol Educ Program. 13–18. 2006. View Article : Google Scholar
15	Puthenparambil J, Lechner K and Kornek G: Auto-immune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: a critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr. 122:229–236. 2010. View Article : Google Scholar : PubMed/NCBI
16	Al-Matham K, Alabed I, Zaidi SZ and Qushmaq KA: Cold agglutinin disease in fibrolamellar hepatocellular carcinoma: a rare association with a rare cancer variant. Ann Saudi Med. 31:197–200. 2011. View Article : Google Scholar : PubMed/NCBI
17	Morris PG, Swords R, Sukor S, Fortune A, O’Donnell DM and Conneally E: Auto-immune hemolytic anemia associated with ovarian cancer. J Clin Oncol. 26:4993–4995. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kim I, Lee JY, Kwon JH, et al: A case of auto-immune hemolytic anemia associated with an ovarian teratoma. J Korean Med Sci. 21:365–367. 2006. View Article : Google Scholar : PubMed/NCBI
19	Park SB, Kim JK, Kim KR and Cho KS: Imaging findings of complications and unusual manifestations of ovarian teratomas. Radiographics. 28:969–983. 2008. View Article : Google Scholar : PubMed/NCBI
20	Valent P and Lechner K: Diagnosis and treatment of auto-immune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr. 120:136–151. 2008. View Article : Google Scholar : PubMed/NCBI
21	Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N and Toi M: Natural killer activity of peripheral- blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 63:703–706. 2009. View Article : Google Scholar : PubMed/NCBI
22	Felder KM, Hoelzle K, Heinritzi K, Ritzmann M and Hoelzle LE: Antibodies to actin in auto-immune haemolytic anaemia. BMC Vet Res. 6:182010. View Article : Google Scholar
23	Terunuma H, Deng X, Dewan Z, Fujimoto S and Yamamoto N: Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 27:93–110. 2008. View Article : Google Scholar : PubMed/NCBI